Natera Stock Plunges 12.65% After Earnings — Adjusted Loss Exceeds Forecast Despite Raised Outlook

Natera lifted its revenue outlook and appointed Solomon Moshkevich CEO, with a plan to double sales.

Share
Natera Stock Plunges 12.65% After Earnings — Adjusted Loss Exceeds Forecast Despite Raised Outlook

Natera, which runs blood-based genetic tests for cancer, women's health and organ health, plunged 12.65% to $317.73 in Friday trading, as of 9:52 a.m. ET, erasing $6.6 billion in market value after earnings and a CEO change. The third-quarter adjusted loss exceeded the forecast even though the company raised its revenue outlook.

A Smaller Loss Still Misses

Natera's adjusted loss came to $0.39 per share for the quarter. Zacks Equity Research had anticipated a loss of $0.17 per share; the year-earlier adjusted loss was $0.64 per share.

The revenue outlook moved in the opposite direction: Natera now expects $3.01 billion to $3.04 billion, compared with its previous range of $2.85 billion to $2.91 billion.

Thursday's earnings release accompanied the appointment of Solomon Moshkevich as CEO, replacing Steve Chapman, according to the company's SEC filing. Chapman remains a consultant and adviser to the board.

A Sharp Retreat From Yearly Gains

NTRA shares were on pace for their biggest one-day decline in at least 275 trading sessions in Friday trading, as of 9:52 a.m. ET. Natera's market value stood at $45.8 billion at that same point in Friday trading.

The stock entered the session with a sizable lead over the wider market. At Thursday's close, Natera was up 59% year-to-date against an 8% gain for the S&P 500, though its shares had fallen 15% over the previous month through Thursday's close.

Moshkevich's Sales-Doubling Plan

On Thursday's earnings call, Moshkevich outlined a plan to double sales, with early cancer screening contributing barely anything to the target.

Natera's existing tests span several uses. Signatera monitors cancer remaining after treatment; Panorama is a prenatal test. The company also offers carrier and hereditary cancer screening, tests for rejection of kidney, heart and lung transplants, and genetic testing for chronic kidney disease.

The Austin, Texas-based company processed about 3.5 million tests in 2025 and reported $2,306.1 million in revenue that year. Its own U.S. sales team and more than 100 laboratory and distribution partners sell its products, which are offered in more than 80 countries.

Natera expects positive free cash flow—cash left after capital spending—in the fourth quarter, according to its earnings-call update.

Sources

More on Natera

All Natera (NTRA) coverage →